Relative risks for myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) and death from sepsis in patients with severe chronic neutropenia (SCN).
| . | ANC at 6–18 months . | ||
|---|---|---|---|
| G-CSF Dose at 6 Months . | ≥ 2188 . | < 2188 . | . |
| *p = 0.008 for likelihood ratio test | |||
| ‡p = 0.094 for likelihood ratio test | |||
| Data are expressed as relative hazard (95% confidence interval) relative to risk of the indicated complication at G-CSF dose < 8 μg/kg/day and ANC ≥ 2188. Adapted from reference 10. | |||
| < 8 μg/kg/day | 1.0 (referent) | 1.7 (0.5–6.4) | MDS/AML |
| 1.0 (referent) | 0.6 (0.05–6.9) | Death from sepsis | |
| ≥ 8 μg/kg/day | 1.7 (0.5–5.5) | 4.5 (1.5–13.4)* | MDS/AML |
| 0.5 (0.04–5.1) | 3.8 (0.79–18.3)‡ | Death from sepsis | |
| . | ANC at 6–18 months . | ||
|---|---|---|---|
| G-CSF Dose at 6 Months . | ≥ 2188 . | < 2188 . | . |
| *p = 0.008 for likelihood ratio test | |||
| ‡p = 0.094 for likelihood ratio test | |||
| Data are expressed as relative hazard (95% confidence interval) relative to risk of the indicated complication at G-CSF dose < 8 μg/kg/day and ANC ≥ 2188. Adapted from reference 10. | |||
| < 8 μg/kg/day | 1.0 (referent) | 1.7 (0.5–6.4) | MDS/AML |
| 1.0 (referent) | 0.6 (0.05–6.9) | Death from sepsis | |
| ≥ 8 μg/kg/day | 1.7 (0.5–5.5) | 4.5 (1.5–13.4)* | MDS/AML |
| 0.5 (0.04–5.1) | 3.8 (0.79–18.3)‡ | Death from sepsis | |